Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"NAD(P)H:quinone oxidoreductase-1 (NQO1)"”.
-
Structure and function of glutamate transporters
… the HIV gp120 envelope protein (gp120) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1). The study of gp120 involved a statistical analysis of substitutions that occur during early infection of clade A HIV, showing that during early infection substitutions are non-random and co-locate in regions …
-
Structure and function of glutamate transporters
… the HIV gp120 envelope protein (gp120) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1). The study of gp120 involved a statistical analysis of substitutions that occur during early infection of clade A HIV, showing that during early infection substitutions are non-random and co-locate in regions …
-
NQO1-Bioactivatable Drugs at the Interface of Cancer Metabolism and the DNA Damage Response
… toxicity. The phase II detoxification enzyme, NAD(P)H:quinone oxidoreductase-1, NQO1, is dramatically overexpressed in many solid tumor types, including pancreatic ductal adenocarcinoma (PDA) and non-small cell lung cancer (NSCLC). The Boothman laboratory has demonstrated that NQO1 bioactivates …
-
Beta-Lapachone Nanotherapeutics for Lung Cancer Therapy
… action relies on its bioactivation by the enzyme NAD(P)H:quinone oxidoreductase-1, NQO1, found overexpressed in NSCLC. While promising, its low water solubility limits its clinical translation. Moreovoer, a clinical formulation of the drug proves highly hemolytic and relatively ineffective. Our …
-
NAD(P)H:QUINONE OXIDOREDUCTASE (NQO1)-DIRECTED LAVENDAMYCIN ANTITUMOR AGENTS: STRUCTURE-BASED DESIGN, MOLECULAR MODELING AND STRUCTURE-ACTIVITY STUDIES
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron reductase that catalyzes an NAD(P)H-dependent activation of many quinone-based antitumor agents. NQO1, expressed at high levels in many human solid tumors, can be used as a target for enzyme-directed bioreductive antitumor drug development. …
-
NAD(P)H:QUINONE OXIDOREDUCTASE (NQO1)-DIRECTED LAVENDAMYCIN ANTITUMOR AGENTS: STRUCTURE-BASED DESIGN, MOLECULAR MODELING AND STRUCTURE-ACTIVITY STUDIES
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron reductase that catalyzes an NAD(P)H-dependent activation of many quinone-based antitumor agents. NQO1, expressed at high levels in many human solid tumors, can be used as a target for enzyme-directed bioreductive antitumor drug development. …
-
Deoxynyboquinones as NQO1-targeted anticancer compounds and deoxynybomycins as potent and selective antibiotics
Made available in DSpace on 2016-03-02T20:57:24Z (GMT). No. of bitstreams: 5 PARKINSON-DISSERTATION-2015.pdf: 21604741 bytes, checksum: 36ce90169c82a68c9b09739d5545d439 (MD5) LICENSE.txt: 4216 bytes, checksum: 30a9874759f4e96d3a10d148120d7757 (MD5) Parkinson Supplemental 1.pdf: 124148 bytes, …
-
Resveratrol Analogs: Potential Chemopreventive Agents in Breast Cancer
… / oxidative stress during its metabolism to quinones. This oxidative stress can be controlled by production of phase-II detoxifying antioxidant enzymes. In order to test this hypothesis we examined the cellular levels of different antioxidant enzymes after treatment with E2. We then …